Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
lupus nephritis
Biotech
Kezar's lupus data spur hope for inflammatory drug
Kezar’s hopes for zetomipzomib as a catch-all drug for inflammatory disease may be over, but a phase 2 readout offers hope in lupus nephritis.
James Waldron
Jun 28, 2022 8:50am
How a Seattle Genetics cancer drug could help lupus patients
Apr 9, 2020 8:35am
Aurinia soars as phase 3 lupus study hits primary endpoint
Dec 5, 2019 7:30am
Aurinia poaches CEO Peter Greenleaf from Cerecor
Apr 12, 2019 10:49am
A CAR-T approach to lupus
Mar 6, 2019 2:26pm
Another setback for AZ as lupus drug fails phase 3 test
Aug 31, 2018 9:20am
